CLAIMS

1. An immediate release pharmaceutical formulation comprising, as an active ingredient, a compound of formula (I) :



(I)

wherein

R^1 is C_{1-2} alkyl substituted with one or more fluoro substituents;

R^2 is hydrogen, hydroxy, methoxy or ethoxy; and

n is 0, 1 or 2;

or a pharmaceutically acceptable salt thereof; and

a pharmaceutically acceptable diluent or carrier; provided that when the active ingredient is other than in the form of a salt, the formulation does not solely contain:

- a solution of one active ingredient and water;
- a solution of one active ingredient and dimethylsulphoxide; or
- a solution of one active ingredient in a mixture of ethanol:PEG 660 12-hydroxy stearate:water 5:5:90.

2. An immediate release pharmaceutical formulation as claimed in claim 1, comprising an acid addition salt of a compound of formula (I) and a pharmaceutically acceptable diluent or carrier.

3. An immediate release pharmaceutical formulation as claimed in claim 1, wherein the active ingredient is:

Ph(3-Cl)(5-$OCHF_2$)-(*R*)CH(OH)C(O)-(*S*)Aze-Pab(OMe);

Ph(3-Cl)(5-$OCHF_2$)-(*R*)CH(OH)C(O)-(*S*)Aze-Pab(2,6-diF)(OMe);

Ph(3-Cl)(5-OCH_2CH_2F)-(*R*)CH(OH)C(O)-(*S*)Aze-Pab(OMe);

Ph(3-Cl)(5-$OCHF_2$)-(*R*)CH(OH)C(O)-(*S*)Aze-Pab;

Ph(3-Cl)(5-$OCHF_2$)-(*R*)CH(OH)C(O)-(*S*)Aze-Pab(OH);

Ph(3-Cl)(5-$OCHF_2$)-(*R*)CH(OH)C(O)-(*S*)Aze-Pab(2,6-diF);
Ph(3-Cl)(5-$OCHF_2$)-(*R*)CH(OH)C(O)-(*S*)Aze-Pab(2,6-diF)(OH);
Ph(3-Cl)(5-OCH_2CH_2F)-(*R*)CH(OH)C(O)-(*S*)Aze-Pab; or
Ph(3-Cl)(5-OCH_2CH_2F)-(*R*)CH(OH)C(O)-(*S*)Aze-Pab(OH).

4. A formulation as claimed in claim 1, wherein the active ingredient is a crystalline salt of:
Ph(3-Cl)(5-$OCHF_2$)-(*R*)CH(OH)C(O)-(*S*)Aze-Pab(OMe);
Ph(3-Cl)(5-$OCHF_2$)-(*R*)CH(OH)C(O)-(*S*)Aze-Pab(2,6-diF)(OMe); or
Ph(3-Cl)(5-OCH_2CH_2F)-(*R*)CH(OH)C(O)-(*S*)Aze-Pab(OMe).

5. A formulation as claimed in claim 1, wherein the active ingredient is an ethanesulfonic acid, *n*-propanesulfonic acid, benzenesulfonic acid, 1,5-naphthalenedisulfonic acid, or n-butanesulfonic acid addition salt of Ph(3-Cl)(5-$OCHF_2$)-(*R*)CH(OH)C(O)-(*S*)Aze-Pab(OMe) or Ph(3-Cl)(5-$OCHF_2$)-(*R*)CH(OH)C(O)-(*S*)Aze-Pab(2,6-diF)(OMe).

6. A formulation as claimed in claim 1, wherein the active ingredient is Ph(3-Cl)(5-$OCHF_2$)-(*R*)CH(OH)C(O)-(*S*)Aze-Pab(OMe), benzene-sulfonic acid salt, characterised by an X-ray powder diffraction pattern characterised by peaks with d-values at 5.9, 4.73, 4.09, and 4.08Å.

7. A formulation as claimed in claim 1, wherein the active ingredient is Ph(3-Cl)(5-$OCHF_2$)-(*R*)CH(OH)C(O)-(*S*)Aze-Pab(2,6-diF)(OMe), hemi-1,5-naphthalenedisulfonic acid salt, characterised by an X-ray powder diffraction pattern characterised by peaks with d-values at 18.3, 9.1, 5.6, 5.5, 4.13, 4.02, 3.86, 3.69, and 3.63Å.

8. A formulation as claimed in claim 1, wherein the composition is selected from a solid immediate release pharmaceutical formulation, an injectable immediate release pharmaceutical formulation, or a liquid immediate release oral pharmaceutical formulation.

9. A method for treating a patient suffering from, or at risk of developing a cardiovascular disorder, comprising administering to the patient a therapeutically effective amount of a pharmaceutical formulation of any one of claims 1 to 8.